Gilead Sciences, Inc.

Carna Biosciences, Inc.

Hirokazu Matsumoto

Masaaki Sawa

Tetsuya Kobayashi

Jonathan William Medley

Leena Patel

Qingming Zhu

Mai Arai

Ryoko Nakai

Michael Graupe

Juan A Guerrero

Suet Chung Yeung

Jie Xu

Julian Andrew Codelli

Yasamin Moazami

Jesse M Jacobsen

Stephen D Holmbo

Heath A Weaver

Takao Kiyoi

Catherine Pugh

Eric Hu

Latesh Lad

Will Watkins

Shiori Takamatsu

The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.

Diacylglycerol kinase modulating compounds

Provided herein are novel compounds having an inhibitory effect on the activation of a STING pathway. The provided compounds are 1,2-diaminobenzimidazole derivatives represented by a compound formula (I) or a pharmaceutically acceptable salt thereof: wherein A, A, R, R, R, R, and Rare defined in the specification.

1,2-diaminobenzimidazole derivative

Growing community of inventors

Kobe, Japan

Hirokazu Matsumoto